Biogen Will Take Alzheimer's Therapy to FDA, Reviving Hope

The transcript discusses the impact of a drug trial on Biogen's stock, focusing on a futility analysis that initially showed the drug might not meet efficacy requirements. However, with more patients added, the trial results improved, sparking optimism about potential approval. The discussion covers the challenges of beta amyloid treatments, Biogen's reliance on multiple sclerosis drugs, and the company's future if the Alzheimer's drug fails. The FDA's role in approving such drugs is highlighted, along with the potential market size. The impact on other biotech stocks and the broader sector is also considered.

What is the significance of the FDA's role in the drug approval process as mentioned in the text?

What potential market size is suggested for the Alzheimer's treatment based on the discussion?